|Bid||137.16 x 0|
|Ask||137.28 x 0|
|Day's Range||137.08 - 138.98|
|52 Week Range||116.12 - 143.00|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||28.90|
|Earnings Date||Jul 21, 2021|
|Forward Dividend & Yield||3.48 (2.53%)|
|Ex-Dividend Date||May 25, 2021|
|1y Target Est||N/A|
A scientist investigating rare blood clots possibly linked to AstraZeneca's and Johnson & Johnson's COVID-19 vaccines has yet to start a planned collaboration with the U.S. company, he said, as talks over their research pact continue. Dr. Andreas Greinacher, a transfusion medicine expert at Germany's Greifswald University, has been studying clotting with low blood platelets in people who got AstraZeneca's vaccine. In April, when clotting developed in a few people who got J&J's shot, Greinacher announced his lab would work with the U.S. company to explore causes.
Is JNJ stock a buy after U.S. regulators recommended vaccinations resume with Johnson & Johnson's Covid vaccine following worries of blood clots? Shares are forming a flat base.
Dr. Amesh Adalja, Senior scholar Johns Hopkins center for health security, joined Yahoo Finance to discuss the latest on covid.